Homeopathy and Anthroposophic Medicine THEIR PLACE IN EUROPEAN HEALTH CARE

Similar documents
European Parliament Interest Group on CAM Brussels, 16 November 2010

Clinical Evidence in the Daily Work of an Anthroposophic Hospital Dr. med. Harald Matthes, Medical Director, Havelhöhe Hospital in Berlin

Smokefree Policies in Europe: Are we there yet?

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

The health economic landscape of cancer in Europe

COMMISSION OF THE EUROPEAN COMMUNITIES

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Nutrient profiles for foods bearing claims

GLP in the European Union Ecolabel detergents, GLP and accreditation

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

2008 EUROBAROMETER SURVEY ON TOBACCO

Where we stand in EFORT

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Underage drinking in Europe

Overview of drug-induced deaths in Europe - What does the data tell us?

Cross Border Genetic Testing for Rare Diseases

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Alcohol Prevention Day

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

REPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU

Rheumatoid Arthritis Disease Burden and Access to Treatment

Pharmacy Ownership and Establishment

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Alcohol-related harm in Europe and the WHO policy response

Meeting report, September 2005

EUROPEAN AEROSOL PRODUCTION

Overview of European Consumption Databases

European Collaboration on Dementia. Luxembourg, 13 December 2006

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

European Status report on Alcohol and Health

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

LEBANON. WCPT COUNTRY PROFILE December 2018

This document is a preview generated by EVS

Sign Language Act in Europe and Hungary by dr. Ádám Kósa

DENMARK. WCPT COUNTRY PROFILE December 2018

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

Monthly measles and rubella monitoring report

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) PROGRAMME RESULTS

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Identifying Europe s information needs for effective drug policy Lisbon, EMCCDA

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

GERMANY. WCPT COUNTRY PROFILE December 2018

European Community Pharmacy: a reference in Public Health

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD AND FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2015

Thomas Karlsson & Esa Österberg National Research and Development Centre for Welfare and Health Alcohol and Drug Research Group P.O.

State of provision of Hearing Aids in Europe

UK bowel cancer care outcomes: A comparison with Europe

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

The cancer burden in the European Union and the European Region: the current situation and a way forward

Highly pathogenic avian influenza "The Epidemic" Regionalisation in the European Union

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

German Pharmacies. Figures Data Facts Legal disclosure:

The Identification of Food Safety Priorities using the Delphi Technique

European status report on alcohol and health Leadership, awareness and commitment

Official Journal of the European Union

MEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

The Risk of Alcohol in Europe. Bridging the Gap June 2004

COMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL

PRODUCT INGREDIENT RELATED HEALTH CLAIMS ASSESSMENT for NU SKIN PHARMANEX PRODUCTS in EUROPE

This document is a preview generated by EVS

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

What s s on the Menu in Europe? - overview and challenges in the first pan- European food consumption survey

Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg

Joint Programming in Neurodegenerative Disease Research (JPND)

EFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director

EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit

L 284/20 Official Journal of the European Union

Risk perception and food safety: where do European consumers stand today?

Cost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Fresh fruit and vegetable production, trade, supply & consumption monitor in the EU-27 (covering ) With the support of:

This document is a preview generated by EVS

Feedback from the Member States questionnaire

CNAPA Meeting Luxembourg September 2016

Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

L 322/24 Official Journal of the European Union

Screening for Cervical Cancer in Europe

The Advisory Board s view. Peter Zimmermann, MD, PhD Consultant Gynecologist and Obstetrician PLUSTERVEYS, Nastola Medical Centre Nastola, Finland

Where do EU Contries set the limit for low risk drinking.

Engagement in language assessment / Regions of Europe

European Partnership for Screening

This document is a preview generated by EVS

COMMISSION RECOMMENDATION. of

Workshop on Accident Analysis and Risk Assessment A JRC Enlargement Workshop

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Transcription:

Homeopathy and Anthroposophic Medicine THEIR PLACE IN EUROPEAN HEALTH CARE

A thriving European tradition Homeopathy and anthroposophic medicine are part of a long-standing European therapeutic tradition with an overall positive safety record first established over two hundred years ago. They are used today by more than 100 million Europeans and enjoy continuous growth in popularity with patients, doctors and practitioners. Three out of four Europeans know about homeopathy and of these 29% use it for their own health care. This represents 100 million Europeans. Between 25% and 40% of European health care practitioners prescribe homeopathy occasionally, 7% on a regular basis. There are 54 000 specialised homeopathic medical doctors and practitioners in Europe and 30 000 doctors who prescribe anthroposophic medicinal products. The industry for homeopathic and anthroposophic medicinal products represents 1% of the European pharmaceutical market and 7% of the European non-prescription market (In 2005 this was equal to 1 771 million at consumer prices). Sales of homeopathic and anthroposophic medicines in Europe are growing by an average 5% a year. The thousands of medicinal products used in these therapies have been safely on the market in Europe for many decades. However, the current European regulatory framework for these medicinal products, rather than leading towards free trade and European harmonisation, is severely inhibiting industry growth and development. Patients, doctors and practitioners are being denied access to the medicines of their choice. France Netherlands Belgium Germany Switzerland Austria Italy Latvia Lithuania Spain Poland Ireland Great Britain Hungary Denmark Portugal Slovakia Norway Czech Republic Luxembourg Sweden Estonia Finland Greece 0,00 0,27 0,11 0,07 0,05 1,17 1,17 0,78 0,58 0,52 0,51 0,37 0,34 0,30 0,28 Three out of four Europeans know about homeopathy, and of these 29% use it for their health care. Source: Commission Report to the European Parliament and Council on the Application of Directives 92/73/EEC and 92/74/EEC, Brussels Com(97) 362 final Consumption of homeopathic and anthroposophic medicinal products per head in euros, 2005 1,00 Source: ECHAMP 2007 1,56 1,23 1,21 2,00 3,00 3,85 3,65 3,50 4,00 5,00 5,19 5,04 4,87 6,00 7,00 7,01 8,00 There is an urgent need for better regulation of homeopathic and anthroposophic medicinal products to preserve this important European industry and to foster development. 2 3

Homeopathy and anthroposophic medicine Homeopathy and anthroposophic medicine work with the body s own forces to stimulate the healing process. Treatment is individualised and different people receive different treatments even if they suffer from the same disease. This individual approach meets a growing need for a more personalised way of healing. Homeopathic and anthroposophic medicinal products cover a broad portfolio of effective, safe and high quality medicines generally derived from natural substances. They can be individually prescribed by a doctor or practitioner or in many cases selected for self-medication. Homeopathy was developed in Europe by the German physician Samuel Hahnemann (1755-1843) more than 200 years ago. All symptoms of a disease - physical, mental and emotional - contribute to the entire picture. The appropriate homeopathic medicinal product is often a reduced dose of the substance which would create a similar symptom picture in a healthy person. A large number of clinical studies demonstrate the effectiveness of homeopathy and anthroposophic medicine and the level of evidence is sufficient to allow their promotion for public health. Regulations governing the manufacture of these medicinal products ensure quality standards equivalent to those of the conventional pharmaceutical industry. Long-term experience demonstrates that the products are intrinsically safe and have only minor side effects. The medicines are relatively inexpensive. These therapies have the potential to generate savings on health care costs through reduced prescribing of medicines and reduced demand for other services. The European Union has an important role to play in encouraging the wider use of homeopathy and anthroposophic medicine as part of an integrated approach to health care in Europe, bringing together mainstream medical science with the best of other traditions. Anthroposophic medicine was founded in Switzerland by Rudolf Steiner PhD (1861-1925) and Ita Wegman MD (1876-1943), a Dutch physician. It treats a person as a whole entity - body, mind, soul and individuality. It ensures that the optimum conditions for health are present, stimulating the self-healing forces of the body rather than relieving the symptoms of disease. It complements conventional medicine with orthodox medical treatments used if necessary. 4 5

The need for better regulation Lack of adequate European legislation has led to a significant reduction in the number of homeopathic and anthroposophic medicinal products on the market over the past fifteen years. Rather than encouraging harmonisation, the current framework is restricting trade, resulting in lack of availability of a wide range of products across Europe. Doctors, practitioners, patients and consumers are deprived of access to the medication of their choice in many Member States. These medicinal products are well-known and well-established. They differ from conventional pharmaceuticals in a number of ways of specific relevance to an efficient and adequate regulation. The current problems stem from the attempt to assimilate them into a legal and regulatory system that was developed for conventional medicinal products, which are largely new and unknown chemical entities. This has resulted in a burden of inappropriate regulatory requirements. The harmonisation process has been further undermined by strong differences of interpretation between the Member States. About ECHAMP ECHAMP is the European Coalition on Homeopathic and Anthroposophic Medicinal Products and represents the vast majority of the industry for these products in Europe. ECHAMP believes that homeopathy and anthroposophic medicine should be fully integrated into health care provision in Europe. It works towards an appropriate European legal and regulatory framework to ensure the easy availability of the full range of these medicinal products, essential for the successful practice and development of these traditional therapies. ECHAMP has over 50 full (company) members. Its associated and corresponding members include national industry organisations and European associations of health care professionals, patients and consumers. The current legal and regulatory framework for homeopathic and anthroposophic medicinal products is severely restricting the industry for these products. There is an urgent need for better regulation to preserve this traditional European industry and foster development, allowing the positive health benefits of these therapies to spread and meeting the demands of the 100 million European citizens who choose to use them. 6 Relevant EU legislation - a brief history 1992 Council Directives 92/73/EEC and 92/74/EEC lay down provisions on homeopathic medicinal products for human and for veterinary use 1997 Commission report on the application of Directives 92/73/EEC and 92/74/EEC regarding Homeopathic Pharmaceutical Products, COM(1997)362 final 2001 Directive 2001/83/EC on the Community code relating to medicinal products for human use consolidates EU pharmaceutical legislation 2003 Commission Directive 2003/63/EC amending Annex I to Directive 2001/83/EC 2004 Directives 2004/24/EC and 2004/27/EC amending Directive 2001/83/EC ECHAMP E.E.I.G. 2008 7

For further information Doctors associations European Committee for Homeopathy (ECH) www.homeopathyeurope.org European Council of Doctors for Plurality in Medicine (ECPM) www.ecpm.org International Federation of Anthroposophic Medical Associations (IVAA) www.ivaa.info Health practitioners associations European Council for Classical Homeopathy (ECCH) www.homeopathy-ecch.org Committee for Alternative Medicine (KAM) www.kam.se Nordic Co-operation Committee for non-conventional Medicine (NSK) www.nsk-center.org Association of Natural Medicine in Europe ev (ANME) www.anme.info Patients associations European Federation of Homeopathic Patients Associations (EFHPA) www.efhpa.eu European Federation of Patients Associations for Anthroposophic Medicine (EFPAM) www.efpam.org Pharmacists association International Association of Anthroposophic Pharmacists (IAAP) www.iaap.org.uk Manufacturers association European Coalition on Homeopathic and Anthroposophic Medicinal Products www.echamp.eu ECHAMP E.E.I.G. European Coalition on Homeopathic and Anthroposophic Medicinal Products Rue Gray 100 B - 1040 Brussels www.echamp.eu Tel.: +32 2 649 94 40 Fax: +32 2 649 41 77 office@echamp.eu